No­vo Nordisk re­mains un­der UK scruti­ny as MHRA con­ducts its own re­view in 'in­cred­i­bly rare' case

The UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency is now re­view­ing No­vo Nordisk’s mar­ket­ing vi­o­la­tion that re­sult­ed in its loss of UK trade group mem­ber­ship last week. No­vo Nordisk was sus­pend­ed on Thurs­day from the As­so­ci­a­tion of the British Phar­ma­ceu­ti­cal In­dus­try (ABPI) for two years af­ter an in­ves­ti­ga­tion by its reg­u­la­to­ry arm found the phar­ma broke its con­duct rules.

MHRA said on Tues­day that its re­view of the Pre­scrip­tion Med­i­cines Code of Prac­tice Au­thor­i­ty (PM­C­PA) in­ves­ti­ga­tion is stan­dard prac­tice. An MHRA spokesper­son em­pha­sized in an email to End­points News that the sit­u­a­tion with No­vo Nordisk is “in­cred­i­bly rare” while al­so not­ing ABPI took “swift and pro­por­tion­ate ac­tion.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN